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INTRODUCTION
GHB has been formerly used as an anesthetic and 
developed into a popular psychoactive drug. GBL is 
primarily used as a solvent in the pharmaceutical 
industry, is a precursor of and following hepatic 
hydrolysis by the 1-4 Lactonase converted to GHB. 
The plasma half-life of GBL is short, can be detected 
only less than one minute and the main active 
metabolite is GHB (Schep et al. 2012). 
The pharmacokinetics of GHB indicate a short ac-
tion. The time to peak serum levels ranges from 36-57 
minutes and the elimination half-life between 30-52 
minutes. Addiction occurs when prolonged, repeated 
GHB use disrupts the balance of brain transmitters and 
circuits controlling reward, memory and cognition lea-
ding to compulsive use. The duration of clinical effects 
are dose-dependent and range from 2.5-4 hours (Schep 
et al. 2012). 
The pharmacodynamics of GHB describes at least 
two distinct binding sites, the GHB- and the GABAB-
receptor. GHB acts as an agonist at the GHB-receptor, 
which causes an excitatory effect, and as a weak anta-
gonist at the GABAB-receptor, which causes an inhibi-
tory effect. Activation of both GHB- and GABAB-
receptors is responsible for the addictive properties of 
GHB. The psychotropic effect involves the release of 
glutamate, as well as the release and inhibition of release 
of dopamine. In defined areas of the brain, activation of 
the GHB-receptor results in the release of glutamate. The 
dopamine release of GHB is biphasic. Low doses of GHB 
stimulate dopamine release via the GHB-receptor, higher 
concentrations then inhibit dopamine release via the 
GABAB-receptor, and eventually, after an initial phase of 
inhibition, dopamine release is again increased via the 
GHB-receptor. More recently, in addition to the action at 
the low-affinity metabotropic GABAB-receptor, a high 
affinity binding site at the inotropic Įȕį-GABAA-receptor
site has been identified. However, the precise role of this 
high-affinity binding site still remains elusive (Bay et al. 
2014, Vogensen et al. 2013).  
The early GHB-withdrawal syndrome resembles the 
alcohol withdrawal syndrome which is associated with 
autonomic instability, tremor, anxiety, restlessness, and 
insomnia. GHB withdrawal usually lasts 3 to 21 days. 
However, severe withdrawal syndromes can produce 
acute delirium and psychosis requiring hospitalization, 
even leading to intensive care management and fatal 
outcome (Schep et al. 2012). The mainstay of manage-
ment of the GHB-withdrawal syndrome remains the 
administration of benzodiazepines which primarily act 
on the GABAA and high doses are often required (van 
Noorden et al. 2009). However, more recently, the 
administration, in particular the titration and tapering of 
GHB itself has been studied with great success. Only a 
low level of withdrawal symptoms was experienced, 
and no patient developed delirium or psychosis (de Jong 
et al. 2012). Thus, administering GHB could be a 
superior future approach in the management of GHB-
withdrawal. Yet another approach, which at this point 
has not yet been evaluated, could be the administration 
of Baclofen, a GABAB-Agonist in conjunction with 
benzodiazepines. This approach would cover the psycho-
dynamic properties of GHB and could be equally useful 
than the administration of GHB. However, this 
approach has not yet been studied to date.  
CASE REPORT 
Mr. V. is a 46 year-old French Male, who was found 
unresponsive in a train from Paris to Zurich. The train 
police was alerted and at the Emergency Department, he 
presented with severe disturbance of consciousness, 
tremor, diaphoresis and muteness. He was afebrile, 
blood pressure and heart rate were elevated. Laboratory 
findings revealed an increased creatinine kinase (1057 
U/l) and myoglobin (178 mcg/l); electrolytes, renal, 
thyroid, and liver function tests were normal, as was the 
cranial CT scan. 
Due to the stupor and mutism - meeting DSM-5 
criteria for the catatonic specifier (APA 2013) - Mr. V. 
was managed with repeated doses of lorazepam, 2.5mg 
every 20 minutes, totaling 7.5mg. Within the hour, his 
consciousness improved, he was able to interact - 
though, did not make sense - severely disoriented, 
cognitively impaired and psychomotor restless. An EEG 
revealed a medication-induced, increased beta-activity. 
The urine toxicology tested positive for GHB. 
Malte Christian Claussen, Katayun Hassanpour, Josef Jenewein & Soenke Boettger: CATATONIC STUPOR SECONDARY  
TO GAMMA-HYDROXY-BUTYRIC ACID (GHB)-DEPENDENCE AND -WITHDRAWAL SYNDROME 
Psychiatria Danubina, 2014; Vol. 26, No. 4, pp 358–359 
359 
On the floor, a severe hyperactive delirium evolved 
with disturbances of consciousness, orientation and 
cognition. The thought process was incoherent, visual 
hallucinations present: He was sitting in his bed 
smoking imaginary cigarettes. The mood was irritable, 
the affect labile and he was agitated. Judgment and 
insight were severely impaired. 
Collateral information revealed that the patient had 
recently lost his job, suffered from recurrent depression 
and ordered unknown substances over the internet. 
Following the working diagnosis, GHB-dependency, 
withdrawal, secondary catatonia and subsequent deli-
rium, Mr. V. was administered increasing amounts of 
lorazepam. Subsequently, after administration of 120mg 
of Lorazepam, the mental status improved. After stabi-
lization, Mr V. admitted to regular use of GBL and 
returned to Paris to his family. 
DISCUSSION 
Mr. V. consumed GBL while being on the train, cau-
sing intoxication and subsequent mechanical rhabdo-
myolysis. In the emergency department he presented 
with a catatonic stupor which responded to lorazepam 
administration before developing a severe delirium due 
to GHB-withdrawal, which in turn was successfully 
managed with increasing doses of lorazepam. 
Catatonia is a syndrome characterized by motor 
immobility and behavioral abnormalities. To date, cata-
tonic stupor has yet not been reported as a consequence 
of GHB-withdrawal, however, has been documented in 
alcohol and abrupt or overly rapid benzodiazepine with-
drawal (Geoffroy et al. 2012, Brown & Freeman 2009).  
Synaptic transmission and neurotransmitters invol-
ved in catatonia include glutamate, GABA and dopa-
mine. The often dramatic response to benzodiazepines 
in catatonia is a crucial observation supporting the role 
of GABA-dysfunction in catatonia. In addition, another 
major theory involves dopamine hypoactivity and gluta-
mate hyperactivity (Dhossche et al. 2010). Thus, it is in 
itself not surprising that GHB-withdrawal, similar to 
alcohol- and benzodiazepine-withdrawal, can manifest 
in a catatonic state. 
A number of facts point to the causative role of 
GHB-withdrawal manifesting as catatonic stupor. For 
one, the absence of medical illness or other findings 
explaining the catatonic presentation, next, the rapid 
response to benzodiazepines, the subsequent withdrawal 
and delirium clearly indicating GHB-withdrawal, as 
well as last, the pathophysiology of catatonia involving 
a hypo-gabaergic state, which could be caused by 
regular GHB-use and withdrawal, indicated that in this 
case, catatonic stupor occurred in the context of GHB-
dependence and –withdrawal. 
CONCLUSION 
In summary, this case illustrates the requirement for 
a heightened awareness of the growing prevalence of 
daily GBL- and GHB-use and -dependence, subsequent 
withdrawal with various presentations including 
delirium, psychosis and catatonia. 
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